BRCA1 Protein

"BRCA1 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). It contains an N-terminal RING FINGER DOMAIN and is a PROTEIN PHOSPHATASE 1 regulatory subunit. In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)

Descriptor ID	D019313
MeSH Number(s)	D12.776.313.125 D12.776.624.776.100 D12.776.660.100 D12.776.744.100 D12.776.930.137
Concept/Terms	BRCA1 Protein BRCA1 Protein Breast Cancer Type 1 Susceptibility Protein Breast Cancer 1 Protein Ring Finger Protein 53 BRCA1 Gene Product Breast Cancer 1 Gene Product

Below are MeSH descriptors whose meaning is more general than "BRCA1 Protein".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Fanconi Anemia Complementation Group Proteins [D12.776.313]
BRCA1 Protein [D12.776.313.125]
Neoplasm Proteins [D12.776.624]
Tumor Suppressor Proteins [D12.776.624.776]
BRCA1 Protein [D12.776.624.776.100]
Nuclear Proteins [D12.776.660]
BRCA1 Protein [D12.776.660.100]
Phosphoproteins [D12.776.744]
BRCA1 Protein [D12.776.744.100]
Transcription Factors [D12.776.930]
BRCA1 Protein [D12.776.930.137]

Below are MeSH descriptors whose meaning is related to "BRCA1 Protein".

Below are MeSH descriptors whose meaning is more specific than "BRCA1 Protein".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "BRCA1 Protein" by people in this website by year, and whether "BRCA1 Protein" was a major or minor topic of these publications.

Bar chart showing 50 publications over 26 distinct years, with a maximum of 6 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1998	1	0	1
1999	1	0	1
2001	1	0	1
2002	2	1	3
2003	0	1	1
2004	2	0	2
2006	4	0	4
2007	1	0	1
2008	1	0	1
2009	1	0	1
2010	2	0	2
2011	2	0	2
2012	1	1	2
2013	1	1	2
2014	1	0	1
2015	1	0	1
2016	1	1	2
2017	0	1	1
2019	2	1	3
2020	1	3	4
2021	6	0	6
2022	1	1	2
2024	2	0	2
2025	2	0	2
2026	0	1	1

Below are the most recent publications written about "BRCA1 Protein" by people in Profiles.

Balkwill FR, Laumont CM, Burdett N, Le Saux O, Garsed DW, Grither WR, Nijhuis AM, Recouvreux MS, Kang Z, Zhang R, Chiappinelli KB, Lee JS, Laniti DD, McNeish I, Ahmed AA, Rottapel R, Conejo-Garcia JR, Odunsi K, Pharoah PDP, Zamarin D, Ishak CA, Fotopoulou C, Buckanovich RJ, Labidi-Galy I, Brenton JD, Lengyel E, Cook DP, George SHL, Lheureux S, Drapkin R, Nephew KP, Adams S, Pathania S, Nelson BH, F?rkkil? A, Fuh K, Neel BG, Bowtell DD. Rethinking ovarian cancer III: the past decade and future directions. Nat Rev Cancer. 2026 Jun; 26(6):452-471.

View in: PubMed
Peng M, Lee S, Nair HG, MacGilvary N, Cong K, Kraemer M, Li R, McConnell J, Baer C, Deng B, Zhu L, Cantor SB. RAD51 is chromatin enriched and targetable in BRCA1-deficient cells. Mol Cell. 2025 Sep 18; 85(18):3373-3387.e6.

View in: PubMed
Whalen JM, Earley J, Silva C, Mercurio AM, Cantor SB. Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability. Nat Cancer. 2025 Feb; 6(2):278-291.

View in: PubMed
Li CM, Cordes A, Oliphant MUJ, Quinn SA, Thomas M, Selfors LM, Silvestri F, Girnius N, Rinaldi G, Zoeller JJ, Shapiro H, Tsiobikas C, Gupta KP, Pathania S, Regev A, Kadoch C, Muthuswamy SK, Brugge JS. Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer. Nat Genet. 2024 Dec; 56(12):2763-2775.

View in: PubMed
MacGilvary N, Cantor SB. Positioning loss of PARP1 activity as the central toxic event in BRCA-deficient cancer. DNA Repair (Amst). 2024 12; 144:103775.

View in: PubMed
Bhardwaj PV, Abdou YG. Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications. Curr Oncol Rep. 2022 12; 24(12):1791-1800.

View in: PubMed
Cong K, Cantor SB. Exploiting replication gaps for cancer therapy. Mol Cell. 2022 07 07; 82(13):2363-2369.

View in: PubMed
Ho PJ, Khng AJ, Loh HW, Ho WK, Yip CH, Mohd-Taib NA, Tan VKM, Tan BK, Tan SM, Tan EY, Lim SH, Jamaris S, Sim Y, Wong FY, Ngeow J, Lim EH, Tai MC, Wijaya EA, Lee SC, Chan CW, Buhari SA, Chan PMY, Chen JJC, Seah JCM, Lee WP, Mok CW, Lim GH, Woo E, Kim SW, Lee JW, Lee MH, Park SK, Dunning AM, Easton DF, Schmidt MK, Teo SH, Li J, Hartman M. Germline breast cancer susceptibility genes, tumor characteristics, and survival. Genome Med. 2021 12 02; 13(1):185.

View in: PubMed
He Y, Rivera J, Diossy M, Duan H, Bowman-Colin C, Reed R, Jennings R, Novak J, Tran SV, Cohen EF, Szuts D, Giobbie-Hurder A, Bronson RT, Bass AJ, Signoretti S, Szallasi Z, Livingston DM, Pathania S. BRCA1/Trp53 heterozygosity and replication stress drive esophageal cancer development in a mouse model. Proc Natl Acad Sci U S A. 2021 10 12; 118(41).

View in: PubMed
Paes Dias M, Tripathi V, van der Heijden I, Cong K, Manolika EM, Bhin J, Gogola E, Galanos P, Annunziato S, Lieftink C, And?jar-S?nchez M, Chakrabarty S, Smith GCM, van de Ven M, Beijersbergen RL, Bartkova J, Rottenberg S, Cantor S, Bartek J, Ray Chaudhuri A, Jonkers J. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. Mol Cell. 2021 11 18; 81(22):4692-4708.e9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals